Dr Reddy’s Faces US Class Action Case Heat
Executive Summary
Pressure builds on Dr Reddy’s Laboratories after at least two US law firms press ahead with a class action case against the company. Analysts appear unperturbed, however – at least for now – about the possibility of any material implications.
You may also be interested in...
Another Dr Reddy’s Plant Runs Afoul Of German Regulator
Dr Reddy’s Laboratories has suffered another blow, with a second manufacturing facility failing to pass muster with the German regulator. While the plant doesn’t currently make supplies to the EU, the firm’s recent run of compliance deviations threatens to erode investor confidence.
FDA Slams Hetero For Oversized Tablets And Dirty Equipment
In a recent FDA warning letter to Hetero Labs in Hyderabad, India, investigators chastise the firm for lax GMP practices. Hetero joins a growing number of manufacturers in the city that have been targeted by FDA and EU regulators for GMP violations this year.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.